European Psychiatry - Volume 41 - April 2017

280 / 916

S276 25th European Congress of Psychiatry / European Psychiatry 41S (2017) S238–S302
observe any inter-group differences in VFT P, SCWT (relative inhibi-
tion) or the GNG. In both patient groups, there appeared significant
correlations between their WCST and TMT scores. The general
neuropsychological profiles were similar in both groups. The DS
patients exhibited slightly greater interference within concept for-
mation and non-verbal cognitive flexibility. Such problems may
therefore be specific to that particular subset of schizophrenia. Our
results may be useful for the development of new rehabilitation
activities, which may increase the chance of the patients’ better
social functioning.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0499
Relapse after first-episode psychosis:
A 3-year follow-up
E. Pereira ∗, M. Mota Oliveira , R. Guedes , M.J. Peixoto , I. Ferraz ,
C. Silveira
Centro Hospitalar de São João, Clinic of Psychiatry and Mental
Health, Porto, Portugal
∗ Corresponding author.
Introduction Relapse after first-episode psychosis (FEP) is a fre-
quent problem, which can lead to patients’ poorer functioning and
response to treatment. Its prevention is one of the most important
and challenging targets in the treatment of psychotic disorders.
Objectives To characterize and evaluate relapse rates after FEP,
during the course of 3 years, of a group of patients admitted at a
psychiatry department.
Methods A retrospective observational study was conducted.
Patients with a FEP between ages 18 to 40, admitted at the Clinic of
Psychiatry and Mental Health at São João Hospital Centre between
January 1, 2007 and September 30, 2013. Only patients with, at
least, 3 years of follow-up at the clinic were included.
Results Final sample of 58 patients, 39 of whichweremale (mean
age = 26.4 years). Forty patients were excluded by not completing
the 3 years follow-up at our department. The cumulative relapse
rates were 32.8% at 12months, 53.4% at 24 months and 63.8%
at 36 months. Patients with at least one relapse were younger
(25.78 years vs. 27.52 years) and had shorter periods of first hos-
pitalization (19.25 days vs. 23.52 days). These data did not reach
statistical significance. Non-adherence to prescribed medication
was described in 73.0% (n = 27) of patients at the time of relapse.
Eight of them (21.6%) presented with cannabis use.
Conclusions Although no statistical significance was reached, our
findings are consistent with other studies. A future studywith a big-
ger sample would be important in achieving statistical significant
results.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0500
Medical comorbidity in schizophrenia
A. Pestana Santos ∗ mílcar Teixeira
Coimbra Hospital and University Centre, Psychiatry, Coimbra,
Portugal
∗ Corresponding author.
People with schizophrenia have higher prevalence of physical dis-
ease and its lifespan is shortened when compared with general
population. On average, they die 10 to 25 years earlier than general
population.
Aim The authors aimto identify themain comorbidities in people
with schizophrenia and define strategies to prevent it.
Methods Literature review on Medline database.
Results People with schizophrenia have higher risk to have
hepatitis, cardiovascular diseases, diabetes, overweight, sexual
dysfunction and obstetric complications. This high vulnerability is
associated with higher rates of preventable risk factors, such as
smoking, alcohol consumption, use of street drugs, poor dietary
habits and lack of exercise. Moreover, some antipsychotic med-
ications used to treat schizophrenia have been associated with
higher incidence of physical disease. At last, there are risk factors
attributable to patients and healthcare services. Psychiatrists are
often not trained in detection and treatment of physical disease.
Despite this, there are several attitudes that can reduce the asso-
ciated morbidity and mortality in people with schizophrenia, such
as improving access to healthcare services, integrated healthcare
interventions to enable early diagnosis and promotion of healthy
habits.
Conclusions Diagnosis and management of morbidity in people
with schizophrenia are more difficult because obstacles related to
the patient, the illness, the medical attitudes and the structure of
the healthcare services. Regardless these difficulties, the increased
frequency of physical disease in people with schizophreniamust be
valued due to improved detection and treatment of medical disease
will have significant benefits for their psychosocial function and
overall quality of life.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0501
Empowerment with Psychotic
Symptoms Scale (EWPSS): Exploratory
study of the scale’s psychometric
properties
M.J. Martins , C. Carvalho , P. Castilho , A.T. Pereira ,
J. Gonc¸ alves Guiomar . Pinto ∗ arques
D. Carreiras Bajouco Macedo
1 Faculty of Psychology and Educational Sciences of the University of
Coimbra, Cognitive and Behavioural Center for Research and
Intervention, Coimbra, Portugal
2 Faculty of Medicine of the University of Coimbra, Psychological
Medicine Department, Coimbra, Portugal
3 University of Azores, Department of Educational Sciences, Ilha São
Miguel, Portugal
4 University of Coimbra, Faculty of Psychology and Educational
Sciences, Coimbra, Portugal
∗ Corresponding author.
Background Empowerment has been defined as the ability to act
autonomously, the willingness to take risks and being aware of
responsibility. The importance of this construct in psychosis has
been emphasized by recovery models. An integrant part of the
Clinical Interview for Psychotic Disorders (CIPD), the EWPSS is a
visual analog scale in which the participants assess their sense
of empowerment regarding symptoms (delusions, hallucinations,
negative symptoms and disorganization). EWPSS focuses on per-
sonal empowerment (self-worth and self-efficacy) as it could apply
to symptoms.
Aims To preliminarily assess the psychometric properties of the
EWPSS in a sample of participants with psychosis.
Methods The sample comprised 22 participants (68.2%
male), 72.7% single, 50% employed, between 19 and 47 years
old (M= 31.05; SD = 7.088), with 4–17 years of education
(M= 11.77; SD = 3.176). The most prevalent diagnosis was
schizophrenia (68.2%) and the participants had a mean of
1.90 hospitalizations (SD = 2.548). The participants were assessed
with the CIPD (EWPSS) and Depression, Anxiety and Stress
Scales-21.
Results EWPSS has shown acceptable reliability for all dimen-
sions (with alphas ranging between .54 and .78). Empowerment